In a 2004-2007 New Jersey Medicaid cohort of 29,601 mothers, 9 percent of white women initiated postpartum mental-health care after delivery, compared with 4 percent of Black women, and Black women's adjusted odds of initiating treatment were less than half those of white women (Kozhimannil et al., Psychiatric Services 2011; PMID 21632730). A 2017 chart review of 314 minority parturients at a South Bronx hospital found that 24 percent of Black women screened positive for postpartum depression on the Edinburgh Postnatal Depression Scale, with similar prevalence between Black-immigrant (24 percent) and African-American (24 percent) subgroups (Doe et al., Archives of Women's Mental Health 2017; PMID 28025705).
Postpartum depression is roughly twice as common in Black US women as in white peers, but Black women receive PPD treatment at less than half the rate. The 2:1 prevalence and 1:2 access gap together describe the editorial fact: the question is not whether Black mothers experience postpartum depression at higher rates. They do. The question is what the structural and cultural barriers between symptoms and care look like, and what changes when a new on-label treatment enters the formulary.
The treatment-access gap is documented, not hypothesized
The Kozhimannil 2011 paper analyzed New Jersey Medicaid administrative claims for 29,601 women who delivered between July 2004 and October 2007 (13,001 white, 13,416 Black, 3,184 Latina). Initiation was defined as a postpartum mental-health-care visit or antidepressant prescription within six months of delivery; follow-up as a refill or second visit; continued care as at least three visits or three antidepressant fills within 120 days (PMID 21632730). Black women's initiation rate was less than half of white women's. Among those who did initiate, Black women had roughly two-thirds the follow-up rate.
A more recent multi-state analysis of the Pregnancy Risk Assessment Monitoring System covering 138,073 patients with births from 2016 to 2019 across 43 states and 2 jurisdictions documented continuing race-and-ethnicity disparities in receipt of postpartum depression screening as one of two named quality-standard components of postpartum care (Interrante et al., JAMA Health Forum 2022; PMID 36239954). The disparity in postpartum depression treatment is not a single-state or single-decade artifact; it has held across cohort and time-period replications.
What the gap is not: the gap is not Black women being more medicated for postpartum mood, in the way that the off-label antipsychotic-prescribing literature has been misframed for Black dementia patients. Our piece on the Auvelity FDA approval and Black-dementia care covered the same direction-flip in dementia. In postpartum depression as in dementia, the US Medicaid evidence consistently shows undertreatment, not overtreatment.
The Superwoman Schema names a help-seeking barrier without pathologizing it
Cheryl Woods-Giscombé, PhD, RN, PMHNP-BC, FAAN, of the University of North Carolina at Chapel Hill School of Nursing, articulated the Superwoman Schema in 2010 from grounded-theory analysis of eight focus groups with demographically diverse African American women (Woods-Giscombé, Qualitative Health Research 2010; PMID 20154298). The schema identifies five intersecting expectations: an obligation to manifest strength, an obligation to suppress emotions, a resistance to vulnerability or dependence, a determination to succeed despite limited resources, and an obligation to help others.
The construct holds both protective benefits and stress-related liabilities. The benefits Woods-Giscombé named: preservation of self and family or community. The liabilities: relationship strain, stress-related health behaviors, and stress embodiment. The Strong Black Woman role widely discussed in Black community discourse and in Black-women's-health literature is the same construct she operationalized academically; subsequent research has used the Giscombé Superwoman Schema Questionnaire to quantify it.
For postpartum depression specifically, the schema offers a conceptual explanation for the help-seeking gap that the Kozhimannil 2011 numbers document: a cultural expectation to manifest strength and suppress emotions makes acknowledging postpartum mood symptoms harder; a resistance to vulnerability or dependence makes asking for treatment harder; an obligation to help others (including a newborn) ranks above acknowledging one's own symptoms. The discipline question for the article is naming the schema without pathologizing it. The schema is not a deficit. It is a documented response to historical and ongoing structural conditions, with both adaptive and maladaptive consequences.
Zuranolone: the first oral PPD-specific therapy, with race data not in the trial abstract
The FDA approved zuranolone (brand name Zurzuvae, by Sage Therapeutics and Biogen) on August 4, 2023, as the first oral therapy specifically labeled for postpartum depression. The phase 3 SKYLARK trial randomized 196 women with severe postpartum depression 1:1 to zuranolone 50 mg per day or placebo for 14 days; the primary endpoint was change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D) score at day 15, with a 45-day follow-up window (Deligiannidis et al., American Journal of Psychiatry 2023; PMID 37491938). At day 15, women on zuranolone showed a 4-point greater HAM-D-score reduction than women on placebo, with continued benefit through day 45. The most common adverse events were somnolence, dizziness, and sedation; the trial reported no loss of consciousness, withdrawal symptoms, or increased suicidal ideation.
A 2024 indirect treatment comparison estimated zuranolone produced roughly 4 to 7 EPDS-points greater symptom reduction than SSRIs at day 15 and day 45 respectively (Meltzer-Brody et al., Journal of Medical Economics 2024; PMID 38523596). The analysis was sponsored by Sage Therapeutics and Biogen and noted that limited population overlap between SKYLARK and the SSRI randomized trials substantially reduced effective sample size after matching. The comparison is the best-available estimate until a head-to-head zuranolone-versus-SSRI trial is conducted.
The race composition of the SKYLARK trial cohort is not reported in the published abstract. Without race-stratified efficacy or safety data from the registration trial, generalization to Black postpartum-depression patients is partially evidenced rather than confirmed. The same data-gap pattern appears in the AXS-05 (Auvelity) registration trials' race data, flagged in our Auvelity coverage above. The zuranolone wholesale acquisition cost and Medicare or Medicaid formulary placement are also not yet at consumer-facing transparency; brand-name newer drugs typically launch at Tier 3 or higher Part D placement, which has historically depressed Black-Medicare uptake.
Three named voices on the evidence layer
Cheryl Woods-Giscombé, PhD, RN, PMHNP-BC, FAAN, is at the University of North Carolina at Chapel Hill School of Nursing and is the original architect of the Superwoman Schema framework cited above.
Katy Backes Kozhimannil, PhD, MPA, was at the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute at the time of the foundational 2011 paper, and is now at the University of Minnesota Rural Health Research Center, as a Distinguished McKnight University Professor and Director per the public roster widely referenced through 2026.
Elizabeth A. Howell, MD, MPP, is Chair of the Department of Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania and the Harrison McCrea Dickson, M.D. and Clifford C. Baker, M.D. Presidential Professor; her published research focuses on racial and ethnic disparities in severe maternal morbidity, preterm birth, and postpartum care experiences.
What the evidence does not yet tell us
Three things the published record does not currently pin down. First, the race composition of the SKYLARK phase 3 trial cohort is not in the abstract; until race-stratified efficacy and safety data appear, the Black-relevance of zuranolone is partially evidenced. Second, the wholesale acquisition cost and Medicare or Medicaid formulary placement of zuranolone for the Black women population the Kozhimannil 2011 paper documented are not yet at consumer-facing transparency. Third, validated EPDS cut-points specific to US Black women have not been established at the same psychometric depth as for Hispanic women; the standard EPDS cut-point developed in primarily white postnatal cohorts is the current screening default.
A reader looking for definitive Black-relevant zuranolone outcome data, Black-specific EPDS cut-point validation, or Medicare-uptake-by-race numbers is looking for evidence the literature does not currently supply. The actionable path is what is documented now.
What you can do this week
Two concrete actions for a Black mother in the postpartum window or a Black woman with a recently delivered family member.
First, ask your postpartum visit clinician about formal Edinburgh Postnatal Depression Scale screening if it has not already been administered. The EPDS is a 10-item self-report screen that detects PPD across the first 12 months postpartum; the 2-question PHQ-2 is also acceptable as an initial screening tool, with the EPDS more PPD-specific. Postpartum-visit attendance is not the same as postpartum-depression screening; the Black Health provider directory lists OB-GYNs, midwives, and primary-care clinicians with verified licenses who can run the screening. Our piece on finding a Black OB-GYN covers the directory search workflow in more detail.
Second, ask about treatment options if the screening is positive. The standard first-line options are an SSRI (sertraline, fluoxetine, escitalopram are common in the postpartum window with established lactation safety data) or a brief course of cognitive behavioral therapy. Zuranolone is now an FDA-approved oral option specifically for postpartum depression; the conversation with the clinician about whether zuranolone is right for you should cover insurance coverage, prior-authorization requirements, and your specific symptom profile. Brand-name newer drugs typically launch at Tier 3 or higher Medicare Part D placement; verifying coverage status before the prescription is written is the practical step. Cost-and-access is the binding constraint that the Kozhimannil 2011 paper documents, and it has not gone away.
Naming the Superwoman Schema as a real cultural construct does not undo it, but it does open the door to recognizing that asking for postpartum-depression care is not a sign of failure to handle motherhood. The schema's documented liabilities include suppressing symptoms past the point where treatment is most effective. The 4 percent Black-women treatment-initiation rate in the Kozhimannil 2011 cohort is not a measure of how well Black mothers are managing PPD on their own. It is a measure of how often the structural and cultural barriers prevented help from reaching women who were eligible for it.
Update plan
We will update this piece when SKYLARK trial race-stratified data become available, when Medicare or Medicaid formulary tier and prior-authorization data on zuranolone publishes, when a head-to-head zuranolone-versus-SSRI trial completes, when validated EPDS psychometric data specific to US Black women is published, or when significant changes to the postpartum depression screening recommendation appear from professional societies.
Citations
- Kozhimannil KB, Trinacty CM, Busch AB, Huskamp HA, Adams AS. Racial and ethnic disparities in postpartum depression care among low-income women. Psychiatric Services 2011;62(6):619-625. PMID 21632730.
- Doe S, LoBue S, Hamaoui A, Rezai S, Henderson CE. Prevalence and predictors of positive screening for postpartum depression in minority parturients in the South Bronx. Archives of Women's Mental Health 2017. PMID 28025705.
- Woods-Giscombé CL. Superwoman schema: African American women's views on stress, strength, and health. Qualitative Health Research 2010;20(5):668-683. PMID 20154298.
- Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, et al. Zuranolone for the Treatment of Postpartum Depression. American Journal of Psychiatry 2023;180(9):668-675. PMID 37491938.
- Meltzer-Brody S, Gerbasi ME, Mak C, Toubouti Y, Smith S. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression. Journal of Medical Economics 2024. PMID 38523596.
- Interrante JD, Admon LK, Carroll C, Henning-Smith C, Chastain P. Association of Health Insurance, Geography, and Race and Ethnicity With Disparities in Receipt of Recommended Postpartum Care in the US. JAMA Health Forum 2022. PMID 36239954.
